Oncotelic Therapeutics, Inc. (OTLC)

Market Cap	42.81M
Revenue (ttm)	n/a
Net Income (ttm)	-1.67M
Shares Out	440.78M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,836
Average Volume	255,910
Open	0.0988
Previous Close	0.0977
Day's Range	0.0929 - 0.0988
52-Week Range	0.0240 - 0.1100
Beta	-0.76
RSI	53.27
Earnings Date	Nov 13, 2025

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute resp...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Vuong Trieu
• Employees: 26
• Stock Exchange: OTCMKTS
• Ticker Symbol: OTLC